Last updated on April 2020

To Evaluate the Safety and Tolerability of Atogepant 10mg 30 mg and 60 mg Once a Day for the Prevention of Migraine in Participants With Episodic Migraine


Brief description of study

To evaluate the safety and tolerability of atogepant 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine.

Clinical Study Identifier: NCT03777059

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.